The estimated Net Worth of Raymond Joseph Tesi is at least $11 Million dollars as of 3 November 2021. Dr Tesi owns over 3,626 units of INmune Bio stock worth over $9,286,899 and over the last 5 years he sold INMB stock worth over $1,277,280. In addition, he makes $455,000 as Co-Founder, Pres, CEO und Chief Medical Officer & Chairman at INmune Bio.
Dr has made over 8 trades of the INmune Bio stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 3,626 units of INMB stock worth $72,520 on 3 November 2021.
The largest trade he's ever made was exercising 30,000 units of INmune Bio stock on 25 August 2021 worth over $117,300. On average, Dr trades about 6,735 units every 55 days since 2019. As of 3 November 2021 he still owns at least 1,490,674 units of INmune Bio stock.
You can see the complete history of Dr Tesi stock trades at the bottom of the page.
Dr. Raymond Joseph Tesi M.D. is the Co-Founder, Pres, CEO, Chief Medical Officer & Chairman at INmune Bio.
As the Co-Founder, Pres, CEO und Chief Medical Officer & Chairman of INmune Bio, the total compensation of Dr D at INmune Bio is $455,000. There are no executives at INmune Bio getting paid more.
Dr D is 65, he's been the Co-Founder, Pres, CEO und Chief Medical Officer & Chairman of INmune Bio since . There are no older and 3 younger executives at INmune Bio.
Raymond's mailing address filed with the SEC is C/O INMUNE BIO INC., 225 NE MIZNER BLVD., SUITE 640, BOCA RATON,, FL, 33432.
Over the last 5 years, insiders at INmune Bio have traded over $5,236,202 worth of INmune Bio stock and bought 82,618 units worth $534,813 . The most active insiders traders include Linda F Powers, Edgardo Jr Baracchini und Inc Xencor. On average, INmune Bio executives and independent directors trade stock every 51 days with the average trade being worth of $117,087. The most recent stock trade was executed by Scott Juda on 25 June 2024, trading 5,000 units of INMB stock currently worth $36,350.
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
INmune Bio executives and other stock owners filed with the SEC include: